Newron Pharmaceuticals S.p.A.
NP5
Rangering i aksjer
#17693
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in... Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
Aksjekurs
$10.40
Markedsverdi
$212.64M
Endring (1 dag)
1.09%
Endring (1 år)
-41.83%
Land
IT
Handel Newron Pharmaceuticals S.p.A. (NP5)
Kategori
Healthcare
Aksjeprishistorikk for Newron Pharmaceuticals S.p.A. (NP5)
Høyeste sluttskurs: $10.24 den 2026-10-01
Laveste sluttskurs: $31.91 den 2015-07-01
Laveste sluttskurs: $31.91 den 2015-07-01
Aksjeprishistorikk for Newron Pharmaceuticals S.p.A. fra 2015 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | -24.57% |
| 2025 | 182.46% |
| 2024 | 72.12% |
| 2023 | 283.57% |
| 2022 | -24.03% |
| 2021 | -24.86% |
| 2020 | -62.21% |
| 2019 | -18.66% |
| 2018 | -28.88% |
| 2017 | -55.22% |
| 2016 | -5.77% |
| 2015 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $536.87 | 25.89% |
US
|
|
| $191.60 | 613.60% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $884.30 | 8.61% |
NL
|
